Want to see ONCY full AI Analyst Report?
ONCY Stock Chart & Stats
$0.86
-$0.01(-1.50%)
At close: 4:00 PM EDT
$0.86
-$0.01(-1.50%)
Day’s Range― - ―
52-Week Range$0.44 - $1.32
Previous CloseN/A
Volume317.18K
Average Volume (3M)1.40M
Market Cap
$63.58M
Enterprise Value$110.07M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Oct 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding127,510,506
10 Day Avg. Volume1,811,495
30 Day Avg. Volume1,402,560
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-22.05
Price to Sales (P/S)0.00
P/FCF Ratio-5.71
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$5.00Price Target Upside481.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA-aligned Registrational PathwayFDA alignment gives pelareorep a defined potential route toward registration in a difficult-to-treat colorectal cancer population. If interim results are supportive, the planned pivotal expansion could reduce development uncertainty and improve the program’s strategic value.
Regulatory Momentum In Anal CancerFast Track designation and reported GOBLET activity strengthen pelareorep’s development position in a setting with limited treatment options after progression. The regulatory status may facilitate interaction with the FDA and help focus resources on a potentially approvable indication.
Multi-indication Clinical PipelineProgress across multiple gastrointestinal cancer cohorts provides more than one clinical opportunity for pelareorep and creates several potential data-driven catalysts for the pipeline. Continued follow-up and completed enrollment also indicate that key programs are advancing toward meaningful readouts.
Bears Say
No Commercial Revenue And Widening LossesThe company remains entirely dependent on clinical development rather than product sales, while losses are widening from an already substantial base. Without commercial revenue, ongoing research progress must be funded externally, increasing financial pressure before any product approval.
Persistent And Increasing Cash BurnPersistent negative cash flow means the business consumes capital to maintain its clinical programs and has not yet demonstrated self-funding capacity. The increase in cash burn raises the amount of financing required over time and can constrain development plans if capital access weakens.
Negative Equity And Balance-sheet DeteriorationNegative equity and a substantially smaller asset base indicate reduced financial flexibility as the company continues funding clinical operations. This deterioration increases reliance on external capital and may make future financing more dilutive or less flexible for existing shareholders.
Oncolytics Biotech News
ONCY FAQ
What was Oncolytics Biotech’s price range in the past 12 months?
Oncolytics Biotech lowest stock price was $0.44 and its highest was $1.32 in the past 12 months.
What is Oncolytics Biotech’s market cap?
Oncolytics Biotech’s market cap is $63.58M.
When is Oncolytics Biotech’s upcoming earnings report date?
Oncolytics Biotech’s upcoming earnings report date is Oct 30, 2026 which is in 7 days.
How were Oncolytics Biotech’s earnings last quarter?
Oncolytics Biotech released its earnings results on Aug 12, 2026. The company reported -$0.079 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.025.
Is Oncolytics Biotech overvalued?
According to Wall Street analysts Oncolytics Biotech’s price is currently Undervalued.
Does Oncolytics Biotech pay dividends?
Oncolytics Biotech does not currently pay dividends.
What is Oncolytics Biotech’s EPS estimate?
Oncolytics Biotech’s EPS estimate is -0.05.
How many shares outstanding does Oncolytics Biotech have?
Oncolytics Biotech has 127,510,506 shares outstanding.
What happened to Oncolytics Biotech’s price movement after its last earnings report?
Oncolytics Biotech reported an EPS of -$0.079 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went down -2.795%.
Which hedge fund is a major shareholder of Oncolytics Biotech?
Currently, no hedge funds are holding shares in ONCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncolytics Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (481.40% Upside)
$5.00 (481.40% Upside)
Blogger Sentiment
Bullish
ONCY Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.96%
12-Months-Change
Fundamentals
Return on Equity
1020.21%
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Oncolytics Biotech
Oncolytics Biotech Inc. is a biopharmaceutical firm in its development stage, dedicated to researching and creating medicinal therapies for cancer. The company's primary asset is pelareorep, an immunotherapeutic agent administered intravenously to combat both solid tumors and blood cancers. Oncolytics Biotech maintains a collaborative development pact with Merck KGaA and Pfizer Inc. This collaboration aims to advance pelareorep when combined with paclitaxel and avelumab—a human anti-PD-L1 antibody—specifically for addressing metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor 2-negative. Additionally, the company partners with PrECOG LLC. Established in 1998, the enterprise operates from its main office in Calgary, Canada.
ONCY Stock 12 Month Forecast
Average Price Target
$5.00
▲(481.40% Upside)
Technical Analysis
Atossa Therapeutics
―
Oramed Pharm
―
Atara Biotherapeutics
―
Zentalis Pharmaceuticals
―
Prelude Therapeutics
―